AlphAIAlphAI — Financial news for AI agents
fool.comSEP 113 min read$AMGN

Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?

Amgen (AMGN) and Revolution Medicines (RVMD) present contrasting investment profiles. Amgen, with $36.7B revenue and $7.7B net income in 2025, offers steady cash flows and a 2.60% dividend. Revolution Medicines, a clinical-stage biotech, has no revenue but reported a $1.1B net loss. Revolution recently gained FDA approval for Daraxonrasib, a potential breakthrough in pancreatic cancer treatment.

Original reporting
fool.com
Published Sep 11, 2026, 5:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 5:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? — source image
Source · fool.com
Decision brief

The 30-second read

$AMGNNeutralHigh
01

Why it matters

Revolution Medicines' approval is a primary catalyst; Amgen receives no new event.

02

Market read

New drug approval for RVMD could drive short‑term upside; Amgen remains a baseline comparison.

03

What to watch

Potential reimbursement challenges and competition from larger pharma.

Relevance 8/10Novelty 8/10Timing: recent FDA approval

Background

The article compares Amgen and Revolution Medicines, focusing on financial metrics and recent FDA approval for RVMD.

Company-level read

Ticker impact

$AMGNNeutralHigh confidence
Context

Amgen is discussed as a comparison subject but no new company-specific event is disclosed.

Expected impact

minimal impact

Evidence & confidence

Amgen's data are historical; no fresh news to move the stock.

$RVMDBullishHigh confidence
Context

Revolution Medicines announced FDA approval of daraxonrasib for metastatic pancreatic cancer.

Expected impact

upward pressure in the near term

Evidence & confidence

Regulatory approval is a material catalyst for a clinical‑stage biotech.

Market effects

Sector

Boosts sentiment for oncology biotech sector.

Regional

U.S. biotech investors may see increased buying.

Global

Highlights progress in RAS‑targeted therapies worldwide.

Counterpoint

What could challenge this read

Approval may be offset by high cash burn and execution risk.

Key entities

  • company
    Amgen

    Large, diversified biotech with stable cash flow.

  • company
    Revolution Medicines

    Clinical‑stage oncology biotech with new drug approval.

Read at source← All news

Related articles

SEP 11
$AMGNHighAI 9/10

Positive Lung Cancer Data Lifts the Case for Amgen and AstraZeneca

Amgen (AMGN) and AstraZeneca (AZN) reported positive late-stage trial results for their combination therapy, Imdelltra and Imfinzi, in extensive-stage small-cell lung cancer. The treatment improved overall survival, progression-free survival, and response rates. Imdelltra generated $513M in sales last year, and the results could expand its use. Amgen's Q2 2026 revenue rose 10%, while AstraZeneca faces investor pressure from recent setbacks.

yahoo.com2 min
SEP 10
$VRTXMed

Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks

Myriad Genetics (MYGN) reported Q2 revenues of $190.7M, down 10.5% YoY, missing estimates. Its stock fell 40.7% to $3.19. Halozyme Therapeutics (HALO) reported $481M in revenues, up 47.7% YoY, beating estimates. Its stock rose 24.5% to $106.74. Amgen (AMGN) reported $10.05B in revenues, up 9.5% YoY, exceeding expectations. Its stock is flat at $391.29. The market has seen shifts in leadership due to AI and geopolitical concerns.

finance.yahoo.com3 min
SEP 10
$AMGNMed

Why is Amgen stock sliding today?

Amgen (AMGN) stock fell 2.2% to $382.67 after HSBC downgraded it to Hold, cutting its price target to $425. The downgrade follows a competitor's clinical trial failure, which impacted Amgen's pipeline prospects. Analysts cited patent expirations and delayed pipeline benefits as concerns, though some reaffirmed Buy ratings due to positive trial data for Imdelltra.

investing.com2 min
SEP 10
$AMGNMedAI 8/10

AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study

Amgen (AMGN) and AstraZeneca (AZN) reported positive phase III study results for their lung cancer drug combination, Imdelltra and Imfinzi, showing improved overall and progression-free survival. The study, DeLLphi-305, evaluated the combination against Imfinzi alone in extensive-stage small-cell lung cancer (SCLC) patients. Both companies highlighted the potential market opportunity, with SCLC accounting for 15% of lung cancers and an estimated 195,000 global cases in 2026. Imdelltra's sales re

theglobeandmail.com2 min